Merck discontinues Nemtabrutinib development after a Phase 3 BELLWAVE-011 assessment found its potential benefits might not outweigh the risks.
Written By: Anshu Gupta, PharmD
Reviewed By: Pharmacally Editorial Team
Merck announced on November 17, 2026, the discontinuation of its clinical development programme evaluating nemtabrutinib for patients with chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and other haematological malignancies.
The decision followed a review of Phase 3 BELLWAVE-011 (NCT06136559) by an external Data Monitoring Committee (eDMC). The committee’s assessment suggested that the potential benefits of nemtabrutinib might not outweigh the risks in the study. Merck subsequently reviewed the totality of available data and confirmed the unfavourable benefit–risk assessment.
Following this review, the company decided to discontinue nemtabrutinib development across its clinical programme. The decision specifically includes two additional Phase 3 studies, BELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851), alongside BELLWAVE-011.
The three studies evaluated nemtabrutinib in different CLL/SLL treatment settings. BELLWAVE-011 compared nemtabrutinib with investigator’s choice of ibrutinib or acalabrutinib in previously untreated patients. BELLWAVE-008 evaluated nemtabrutinib against chemoimmunotherapy in previously untreated patients without TP53 aberrations, while BELLWAVE-010 investigated nemtabrutinib in combination with venetoclax against venetoclax plus rituximab in patients with relapsed or refractory disease following at least one prior therapy.
Nemtabrutinib and Its Investigational Mechanism
Nemtabrutinib (MK-1026) is an investigational, orally administered, non-covalent BTK inhibitor designed to suppress oncogenic B-cell receptor signalling. BTK plays an important role in B-cell receptor signalling, a pathway involved in B-cell activation and survival.
Targeting this pathway represents an established area of therapeutic research in B-cell malignancies. Nemtabrutinib was developed to inhibit BTK through a non-covalent mechanism and was evaluated across multiple clinical studies under Merck’s BELLWAVE programme.
However, its pharmacological rationale did not establish a favourable clinical benefit–risk profile. The findings reviewed by Merck ultimately led the company to discontinue further development.
Patient Communication and Further Data Analysis
Merck confirmed that it is informing investigators involved in the affected clinical studies about the discontinuation. Patients participating in these trials have been advised to consult their study teams and physicians regarding next steps and appropriate treatment options.
The company also confirmed that analyses of the clinical trial data are ongoing and that results will be shared with the scientific community.
The November 17 announcement did not disclose detailed efficacy results, specific safety findings or individual clinical events underlying the eDMC assessment. Consequently, the precise factors contributing to the unfavourable benefit–risk conclusion remain unclear.
Dr. Marjorie Green, Senior Vice President and Head of Global Oncology Clinical Development at Merck Research Laboratories, stated that the decision followed careful analysis of BELLWAVE-011 data. She also acknowledged the contributions of patients, caregivers and investigators involved in the studies.
Merck reiterated its commitment to developing treatments for patients with haematological malignancies and advancing its broader haematology research pipeline.
Clinical Interpretation
The discontinuation highlights the importance of demonstrating an acceptable benefit–risk profile throughout clinical development, particularly in late-stage comparative trials. Although BTK inhibition is an established therapeutic approach in B-cell malignancies, individual inhibitors must demonstrate their clinical value through their own efficacy and safety findings.
BELLWAVE-011 was designed to compare nemtabrutinib with established BTK inhibitors, ibrutinib and acalabrutinib, in previously untreated CLL/SLL. The decision to discontinue the programme following the eDMC assessment underscores the importance of comparative clinical evidence when evaluating investigational treatments against existing therapeutic options.
However, the absence of detailed trial results means that the decision cannot yet be attributed to a specific efficacy endpoint, adverse event or safety signal. The forthcoming data analyses will be important for understanding the findings behind Merck’s decision and their implications for future BTK inhibitor research.
For now, the discontinuation represents a setback for nemtabrutinib’s development rather than evidence against BTK inhibition as a therapeutic strategy.
References
Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib, Merck & Co., Inc., November 17, 2026.
BELLWAVE-008 – NCT05624554, https://clinicaltrials.gov/study/NCT05624554
BELLWAVE-010 – NCT05947851, https://clinicaltrials.gov/study/NCT05947851
BELLWAVE-011 – NCT06136559, https://clinicaltrials.gov/study/NCT06136559
About the Writer
Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.
